Published in Genetics and Environmental Business Week, August 17th, 2006
Mayo has obtained a nonexclusive license from Pathway Diagnostics, Inc. to test for a key genetic marker that identifies people who respond differently to antidepressants, including selective serotonin reuptake inhibitors (SSRI). SSRIs act specifically by binding to the serotonin transporter, and increase the concentration of the neurotransmitter serotonin in the synapse. These medications include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa) and escitalopram (Lexapro).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.